The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors.
 
Archana Agarwal
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Rebecca Nagy
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Catherine Curran
No Relationships to Disclose
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Richard B. Lanman
Employment - Guardant Health; Veracyte
Leadership - Biolase; Guardant Health
Stock and Other Ownership Interests - Biolase; Forward; Guardant Health
Consulting or Advisory Role - Forward
Research Funding - Guardant Health
 
AmirAli Talasaz
Employment - Guardant Health
Leadership - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Research Funding - Guardant Health
Patents, Royalties, Other Intellectual Property - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group